ArticleInfectious disorders drug targets2022
The Emergence of Omicron SARS-CoV-2 Variant (B.1.1.529): The Latest Episode in the COVID-19 Pandemic with a Global Riposte.
Article in Infectious disorders drug targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over two years after the start of the SARS-CoV-2 epidemic, which has demised over 5 million people, the world is still on high COVID-19 alert in February 2022, and new variants are emerging. Since January 2020, the World Health Organization (WHO) has been closely monitoring and analyzing the evolution of SARS-CoV-2 in partnership with national authorities, public health organizations, and scientists. To prioritize global monitoring and research and to guide the continuing global response to the COVID-19 pandemic, distinct SARS-CoV-2 variants were labelled as Variant of Interest (VOI) and Variant of Concern (VOC). The World Health Organization and its international sequencing networks are constantly monitoring SARS-CoV-2 mutations and informing countries about any adjustments that may be required to respond to the variant and, where possible, prevent its spread. Since January 2021, multiple viral variations have evolved and grown dominant in numerous countries, with the Alpha, Beta, Gamma, and Delta varieties being the most prevalent too far. On November 20, 2021, Omicron was born into a COVID-19-weary world, replete with rage and resentment at the pandemic's broad detrimental effects on social, emotional, and economic well-being. Although earlier VOCs originated in a world where natural immunity to COVID-19 infections was widespread, the fifth VOC, Omicron, has emerged in an environment where vaccine immunity is rising.
Indexed as
Identifiers
35466885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.